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Background
TSH-secreting tumours are extremely rare case of
hyperthyroidism. Most important clinical feature is pre-
served TSH level in subjects with apparent thyrotoxicosis.
Possible misdiagnosis of primary thyroid hyperfunction
could lead to mistreatment with anti-thyroid medications.
This worsens disease course and outcome. Neurosurgery
success rate is limited by tumour size and its extrasellar
expansion. Native somatostatin is key negative regulator of
TSH secretion. In most cases tumour cells express soma-
tostatin receptors. This feature creates potential use of
somatostatin analogues for medical treatment of TSH-
secreting tumours.
Aim of the study
The aim was to determine potential value of somatostatin
analogues in primary TSH-oma treatment. Secondary
objective was to evaluate efficacy of long-acting somatosta-
tin analogues in cases after unsuccessful neurosurgery.
Material
Material comprised of 17 patients with secondary thyro-
toxicosis, 7 women and 10 men, aged 20 to 69 years
(mean 39), presenting with pituitary macroadenoma (16)
and one with microadenoma and empty sella. Before diag-
nosis was established 8 out of 17 patients received antith-
yroid medication, in 2 cases strumectomy was performed
and 2 patients received 131I therapy.
Intervention
Somatostatin analogue octreotide long acting repeatable
(LAR) administration at least 3 months (3 injections)
before surgery, and in cases of unsuccessful surgery
stable octreotide LAR therapy.
Results
Initially, all patients had elevated fT4 and a-SU levels
(mean 29.3 pmol/l SD 4.3, and 6.2 ng/ml SD 4.9). 3 months
of octreotide LAR therapy led to significant fT4 reduction
(to mean 12.2 pmol/l) and TSH reduction from mean
6.5 mIU/ml to 0.3 mIU/l). In all cases clinical improve-
ment was observed.
In 14 out of 17 pre-treated with octreotide LAR
decreased tumour volume and in 2 improvement in
visual field was observed.
Patients in euthyroid state were referred to neurosurgery
department. Transsphenoidal adenomectomy was success-
ful 13 out of 17. In four cases after unsuccessful neurosur-
gery intervention stable euthyroidism was achieved with
octreotide LAR treatment. In one case secondary thyro-
toxicosis relapsed 2 years and now is controlled by octreo-
tide treatment.
Conclusions
Somatostatin analogue treatment is efficient in TSH-
secreting tumours in the terms of TSH secretion, thyroid
function and clinical improvement. In cases of surgery
failure prolonged octreotide treatment could be safe and
efficient option of disease management.
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